@misc{oai:repo.qst.go.jp:00080656,
 author = {Sudo, Hitomi and Tsuji, Atsushi and Sugyo, Aya and Fujiwara, Kentaro and Mika Kaneko and Yukinari Kato and Higashi, Tatsuya and Sudo, Hitomi and Tsuji, Atsushi and Sugyo, Aya and Fujiwara, Kentaro and Higashi, Tatsuya},
 month = {Oct},
 note = {Podoplanin (PDPN) is a glycoprotein that is highly expressed in malignant mesothelioma. We previously showed an anti-PDPN antibody NZ-12 has the potential as a new therapeutic agent for malignant mesothelioma. Here, we developed a novel anti-PDPN antibody NZ-16 having a different constant region from NZ-12. The in vitro and in vivo properties of radiolabeled NZ-16 and the antitumor effects were evaluated in mesothelioma and glioblastoma xenograft mouse models. In vitro assays showed radiolabeled NZ-16 has a higher affinity to PDPN-expressing cells H226 mesothelioma cells and LN319 glioblastoma cells than radiolabeled NZ-12. In vivo biodistribution studies showed high uptake of radiolabeled NZ-16 in H226 and LN319 tumors. Radioimmunotherapy (RIT) with radiolabeled NZ-16 significantly suppressed tumor volumes without obvious adverse events such as body weight loss in both models. The antitumor efficacy of radiolabeled NZ-16 was higher than that of NZ-12. Our findings suggest that RIT with radiolabeled NZ-16 has the potential as a superior therapeutic option for PDPN-expressing tumors., 第79回日本癌学会学術総会},
 title = {A novel anti-podoplanin antibody NZ-16 has the potential as a radioimmunotherapy agent for solid tumors},
 year = {2020}
}